Small molecular inhibitors for KRAS-mutant cancers

Three rat sarcoma (RAS) gene isoforms, KRAS, NRAS, and HRAS, constitute the most mutated family of small GTPases in cancer. While the development of targeted immunotherapies has led to a substantial improvement in the overall survival of patients with non-KRAS-mutant cancer, patients with RAS-mutant...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xuan, Song, Wenping, Cheng, Cheng, Liu, Ziyang, Li, Xiang, Cui, Yu, Gao, Yao, Li, Ding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470052/
https://www.ncbi.nlm.nih.gov/pubmed/37662925
http://dx.doi.org/10.3389/fimmu.2023.1223433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470052/
https://www.ncbi.nlm.nih.gov/pubmed/37662925
http://dx.doi.org/10.3389/fimmu.2023.1223433

Ejemplares similares